Polygenic Risk Score Shows Promise in Predicting Future Breast Cancer in Early-Stage Patients
A new study reveals that a 313-gene polygenic risk score can predict the future risk of breast cancer in women with early-stage diagnoses, offering a promising tool for personalized treatment planning.
Recent research indicates that a blood test utilizing a polygenic risk score (PRS) based on 313 genetic markers (SNPs) can help forecast the likelihood of developing breast cancer in women diagnosed with early-stage conditions such as ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS). Published in ancer Epidemiology, Biomarker & Prevention , this study analyzed data from over 2,300 women, including 2,169 with DCIS and 185 with LCIS.
The study found notable associations between PRS scores and breast cancer risk. Women with DCIS in the highest risk quartile were more than twice as likely (2.03 times) to develop cancer in the opposite breast (contralateral) compared to those in the lowest quartile. However, this score did not significantly correlate with new cancer in the same breast (ipsilateral). Conversely, among LCIS patients, higher PRS scores were linked with a greater risk of cancer in the same breast, increasing the risk by over two times.
Family history further influenced these risks, with women having a familial background of breast cancer experiencing more than a threefold increase in ipsilateral cancer risk when their PRS was high. Excluding those who underwent mastectomy and radiotherapy amplified this risk to four times.
The findings suggest that PRS can be a valuable tool in personalizing treatment plans. By integrating genetic risk scores with traditional diagnostic information, clinicians could better identify women at heightened risk who might benefit from additional preventive therapies, potentially reducing unnecessary treatments.
While promising, the researchers acknowledge limitations, such as the specific design of PRS for invasive disease rather than in-situ conditions and the relatively small cohort of LCIS cases. Further research is essential to validate these results across diverse populations and to assess additional genetic factors.
Overall, the study advances the potential of genomic tools in enhancing breast cancer risk assessment and guiding more tailored therapeutic decisions, ultimately aiming to improve patient outcomes.
source: https://medicalxpress.com/news/2025-09-polygenic-score-future-breast-cancer.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Proteins Regulating NMDA Receptor Function Offer New Hope for Autism Treatments
A groundbreaking study uncovers how proteins like MDGA2 and EphB2 regulate NMDA receptor activity, paving the way for targeted autism treatments and better understanding of synaptic regulation in the brain.
Advancements in 3D-Printed Lung Models for Better Disease Study and Treatment
Researchers are developing 3D-printed lung models that could revolutionize disease study and personalized treatment, paving the way for improved therapies and potential lung regeneration.
Research Links Certain Antibodies in Lupus Patients to Increased Risk of Blood Clots
A breakthrough study identifies specific antibodies in lupus patients that significantly increase their risk of blood clots, paving the way for better risk assessment and targeted treatments.
Global Variations in End-of-Life Care for ALS Patients: A Cross-Cultural Perspective
A cross-cultural study reveals significant international differences in how physicians approach life support decisions for ALS patients, influenced by cultural norms and healthcare systems. Learn about the diverse ethical and practical considerations shaping end-of-life care worldwide.